Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and apipeline of biosimilars, today announced the companyhasreached licensing and ...
BAT1706 is Bio-Thera Solutions’ second EMAapproved product BAT1706 is Bio-Thera Solutions’ secondproduct receiving marketing authorization from NMPA, FDA and EMA Guangzhou, China– July 30, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-sta...
Guangzhou, China– July 25, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announced thatdosing has recently begun in an integrated Phase I ...
